CoChat

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy

Open access

The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index; 7 of the 10 sources its claims cite were checked for support.

Abstract

BACKGROUND: Precision oncology seeks to integrate multiple layers of data from a patient's cancer to effectively tailor therapy. Conventional chemotherapies are sometimes effective but accompanied by adverse events, warranting the identification of a biomarker of chemosensitivity. OBJECTIVE: Identify an mRNA biomarker that predicts chemosensitivity across solid tumor subtypes. METHODS: We performed a pan-solid tumor analysis integrating gene expression and drug sensitivity profiles from 3 cancer cell line datasets to identify transcripts correlated with sensitivity to a panel of chemotherapeutics. We then tested the ability of an mRNA biomarker to predictive clinical outcomes in cohorts of patients with breast, lung, or ovarian cancer. RESULTS: Expression levels of several mRNA transcripts were significantly correlated with sensitivity or resistance chemotherapeutics in cancer cell line datasets. The only mRNA transcript significantly correlated with sensitization to multiple classes of DNA-damaging chemotherapeutics in all 3 cell line datasets was encoded by Schlafen Family Member 11 (SLFN11). Analyses of multiple breast, lung, and ovarian cancer patient cohorts treated with chemotherapy confirmed SLFN11 mRNA expression as a predictive biomarker of longer overall survival and improved tumor response. CONCLUSIONS: Tumor SLFN11 mRNA expression is a biomarker of sensitivity to an array of DNA-damaging chemotherapeutics across solid tumor subtypes.

Overview

CoChat Summary

TL;DR

This pan-cancer analysis identified SLFN11 mRNA as the only transcript consistently associated with sensitivity to multiple classes of DNA-damaging chemotherapeutics across three cancer cell line datasets. Clinical cohort analyses in breast, lung, and ovarian cancer supported SLFN11 mRNA as a biomarker of better survival and/or better response to chemotherapy.

Key findings

  • Across CTRP, GDSC, and NCI60, Pearson correlations were computed for 2,020,930 gene-drug combinations using 27, 17, and 47 chemotherapeutics and 18,988, 17,737, and 25,675 transcripts, respectively; 13,458 genes were shared across all 3 datasets.
  • SLFN11 was the only mRNA transcript significantly correlated with sensitization to multiple classes of DNA-damaging chemotherapeutics in all 3 cell line datasets, and was the only transcript correlated with sensitivity to at least half of tested drugs in 4/5 classes in ≥2 databases.
  • In clinical data, high SLFN11 expression was associated with improved outcomes in selected chemotherapy-treated cohorts: breast cancer HR = 4.32, p = 0.017; one lung cancer HR = 3.72, p = 0.031 and another lung dataset HR = 2.29, p = 0.057; ovarian cancer HR = 1.79, p = 0.05.
  • In treatment-naïve response cohorts, patients with complete response had higher baseline SLFN11 expression: 115 breast cancer patients, p = 0.045; 75 ovarian cancer patients, p = 0.057.

Methods

  • Pan-solid tumor correlation analysis integrating transcriptomic and drug sensitivity data from CTRP (860 cell lines, 481 drugs), GDSC (1,065 cell lines, 266 drugs), and NCI60 (60 cell lines, 783,538 compounds and drugs), limited to solid tumor lineages.
  • Correlated all individual mRNAs with drug sensitivity measures (AUC or IC50) using Pearson correlations; genes were selected when R > 0.2 in >50% of drugs in a chemotherapy class in ≥2/3 databases.
  • Validated SLFN11 in clinical GEO datasets (GSE37751, GSE29013, GSE37745, GSE17260, GSE32646, GSE63885) using median split survival analyses, plus response comparisons by t-test for breast and ovarian cohorts.

Limitations

  • The paper states that some clinical datasets had limited microarray platforms without SLFN11 probes and were therefore excluded.
  • Several reported clinical associations were based on small or statistically limited samples (for example, the ovarian response cohort of 75 patients; stated in the paper).
  • Evident from the text: the study is largely retrospective and correlative, so it supports association rather than direct causal proof of SLFN11’s predictive role.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0224267

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 SLFN11 mRNA levels are strongly correlated with sensitivity to chemotherapeutics in cancer cells. A) mRNA levels for each gene were compared with drug sensitivity to a panel of chemotherapeutics across the CTRP (IC50), GDSC (AUC), and NCI60 (IC50) datasets. Pearson correlation values were plotted for each gene for SN38, mitomycin, and gemcitabine as representative chemotherapeutics. B) SLFN11 mRNA levels were compared with drug sensitivity as in (A) by Pearson correlation. Each point represents the IC50 of a given drug. Horizontal lines indicate mean ± SEM for each drug class. Black filled, white-filled, and color-filled symbols indicate p≤0.001, p≤0.05, and p>0.05, respectively.
Fig 1 SLFN11 mRNA levels are strongly correlated with sensitivity to chemotherapeutics in cancer cells. A) mRNA levels for each gene were compared with drug sensitivity to a panel of chemotherapeutics across the CTRP (IC50), GDSC (AUC), and NCI60 (IC50) datasets. Pearson correlation values were plotted for each gene for SN38, mitomycin, and gemcitabine as representative chemotherapeutics. B) SLFN11 mRNA levels were compared with drug sensitivity as in (A) by Pearson correlation. Each point represents the IC50 of a given drug. Horizontal lines indicate mean ± SEM for each drug class. Black filled, white-filled, and color-filled symbols indicate p≤0.001, p≤0.05, and p>0.05, respectively.CC BY · PubMed Central
Fig 2 SLFN11 mRNA expression is commonly associated with chemosensitivity in cancer cell lines. Numbers of genes with expression correlated with sensitivity (R≤-0.2) or resistance (R≥0.2) to >50% of drugs within a class in ≥2 databases (CTRP, GDSC, or NCI60) are indicated. Genes are listed in Table 2.
Fig 2 SLFN11 mRNA expression is commonly associated with chemosensitivity in cancer cell lines. Numbers of genes with expression correlated with sensitivity (R≤-0.2) or resistance (R≥0.2) to >50% of drugs within a class in ≥2 databases (CTRP, GDSC, or NCI60) are indicated. Genes are listed in Table 2.CC BY · PubMed Central
Fig 3 SLFN11 expression is associated with improved survival outcomes in breast, lung, and ovarian cancer patients treated with chemotherapy. RNA expression and survival data were obtained for primary breast, lung, and ovarian tumors from 4 datasets containing information from 61 breast cancer patients (A/D), 55 and196 lung cancer patients (B/E and C/F, respectively), and 110 ovarian cancer patients (G). Patients were dichotomized into High vs. Low tumor SLFN11 mRNA based on expression above or below the median. Survival analyses were performed for all patients in aggregate in (A-C), and only for patients who received chemotherapy (D-G). Groups were compared by log-rank test.
Fig 3 SLFN11 expression is associated with improved survival outcomes in breast, lung, and ovarian cancer patients treated with chemotherapy. RNA expression and survival data were obtained for primary breast, lung, and ovarian tumors from 4 datasets containing information from 61 breast cancer patients (A/D), 55 and196 lung cancer patients (B/E and C/F, respectively), and 110 ovarian cancer patients (G). Patients were dichotomized into High vs. Low tumor SLFN11 mRNA based on expression above or below the median. Survival analyses were performed for all patients in aggregate in (A-C), and only for patients who received chemotherapy (D-G). Groups were compared by log-rank test.CC BY · PubMed Central
Fig 4 Patients with tumors highly responsive to chemotherapy have high SLFN11 transcript levels. Z-score normalized RNA expression and tumor response data were obtained for primary breast and ovarian tumors from 2 datasets containing information from 115 breast cancer patients (A) and 75 ovarian cancer patients (B) treated with neoadjuvant chemotherapy. Breast cancer patients were divided into patients who had a pathologic Complete Response after chemotherapy (pCR), to those that did not (non-pCR), and SLFN11 expression was compared by Student t-test with Welch’s correction. Ovarian cancer patients were divided into patients who were highly sensitive (HS; defined as DFS>732 days according to [15]) or not (non-HS), and analyzed as above.
Fig 4 Patients with tumors highly responsive to chemotherapy have high SLFN11 transcript levels. Z-score normalized RNA expression and tumor response data were obtained for primary breast and ovarian tumors from 2 datasets containing information from 115 breast cancer patients (A) and 75 ovarian cancer patients (B) treated with neoadjuvant chemotherapy. Breast cancer patients were divided into patients who had a pathologic Complete Response after chemotherapy (pCR), to those that did not (non-pCR), and SLFN11 expression was compared by Student t-test with Welch’s correction. Ovarian cancer patients were divided into patients who were highly sensitive (HS; defined as DFS>732 days according to [15]) or not (non-HS), and analyzed as above.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 0 Not valid · 1 Not checked · 20 Own results and interpretations

14 more claims

Create a free account to see all 28 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 2
  • It may state two separate claims as one. 7

Create a free account to see these claims.

Citations

Cites

Cited by

See all 43

Metadata

Authors
Shee, K., Wells, J. D., Jiang, A., & Miller, T. W.
Affiliations
Dartmouth College (US)
Corresponding author
Miller, Todd W.
Venue
PLOS ONE
Published
2019-11-04
Volume
14
Issue
11
Pages
e0224267
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2983197547
Cited by
43
References
48
Citations by year
2026: 3 · 2025: 5 · 2024: 8 · 2023: 3 · 2022: 3 · 2021: 16 · 2020: 5
FWCI
1.89
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • National Cancer Institute (R01CA211869, F30CA216966, P30CA023108, R01CA200994)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
SLFN11, chemosensitivity biomarker, DNA-damaging chemotherapy, solid tumors, pan-cancer analysis, gene expression, drug sensitivity, cancer cell lines, breast cancer, lung cancer, ovarian cancer, overall survival, precision oncology
MeSH terms
Progression-Free Survival, Antineoplastic Agents, DNA Damage, Female, Humans, Neoplasms, Nuclear Proteins, Predictive Value of Tests, Prognosis, RNA, Messenger, Time Factors, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Survival Analysis, Drug Resistance, Neoplasm, Gene Expression Profiling, Cell Line, Tumor, Precision Medicine, Datasets as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.